<DOC>
	<DOCNO>NCT01168596</DOCNO>
	<brief_summary>The purpose research study determine rasagiline effective treatment fatigue patient Parkinson 's disease ( PD ) .</brief_summary>
	<brief_title>Rasagiline Symptomatic Treatment Fatigue Parkinson 's Disease</brief_title>
	<detailed_description>Despite fact fatigue affect 40-50 % patient PD lead cause disability , currently effective treatment symptom . Rasagiline well-tolerated effective treatment motor symptom PD . Rasagiline MAO-B inhibitor may decrease breakdown dopamine . Many patient report improvement energy level medication . A proven treatment PD fatigue would significantly improve quality life numerous patient caregiver .</detailed_description>
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Fatigue</mesh_term>
	<mesh_term>Rasagiline</mesh_term>
	<criteria>1 . A clinical diagnosis idiopathic PD movement disorder specialist . All subject diagnose use UK Brain Bank criterion ( Hughes et al. , 1992 ) . 2 . Age 4085 year . 3 . Able sign understand inform consent ; cognitively able carry procedure study 4 . Stable PD medication least 30 day ; psychotropic medication least 90 day . 5 . Treatment naïve subject appropriate candidate begin MAOinhibitor monotherapy treatment PD may also include study . 6 . Fatigue Severity Scale ≥ 36 ( KRupps et al. , 1989 ) 1 . Clinically significant medical disease associate independently fatigue ( e.g . significant cardiac pulmonary disease , anemia , obstructive sleep apnea , liver kidney failure ) . 2 . History neurological illness PD history significant head trauma ( involve unconsciousness ) . 3 . Evidence secondary atypical parkinsonism suggest presence following : 1 ) history stroke ( ) , 2 ) exposure toxins neuroleptic , 3 ) history encephalitis , 4 ) neurological sign upper motor neuron disease , cerebellar involvement , supranuclear gaze palsy , significant orthostatic hypotension . 4 . MRI CT scan significant evidence brain atrophy abnormality ( e.g . lacunar infarct iron deposit putamen . 5 . Clinical diagnosis dementia ; MMSE score &lt; 25 . 6 . Unstable , newly diagnose , newly treat ( i.e . le 3 month ) major psychiatric disorder depression anxiety 7 . Beck 's Depression Inventory score &gt; 14 . 8 . Current prior placement Deep Brain Stimulator . 9 . Currently take MAOB inhibitor medication use fatigue treatment , include amantadine , modafinil , methylphenidate , atomoxetine psychostimulants . 10 . Previously take MAOB inhibitor 2 week . 11 . Hypersensitivity rasagiline product 12 . On mirtazapine , venlafaxine , regular use compound vasoconstrictor , tramadol , meperidine , propoxyphene , dextromethorphan , St. John 's wort , cyclobenzaprine 13 . On omeprazole , ciprofloxacin drug metabolize CYP1A2</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>September 2012</verification_date>
	<keyword>Parkinson 's Disease</keyword>
	<keyword>Fatigue</keyword>
</DOC>